Contact Us Today!

Contact Us Today!

  • Message

(908) 272-0200

Publications

THE ROLE OF THE PUBLIC SAFETY ASSESSMENT IN PRETRIAL...

07/18/2019

Bail reform is a hot topic and the public safety assessment (PSA) is a pretrial risk assessment that was introduced through the Criminal Justice Reform Act.   In an...

The Use of Social Media in Preparation For and During...

05/30/2019

Social media (e.g., Facebook, Twitter, Instagram) has impacted Americans’ lives in unpredictable and material ways and, unsurprisingly, now impacts preparing for and...

CMS Drug Price Proposal Would Harm Patients,...

11/02/2018

On October 25th, the Centers for Medicare and Medicaid Services released a proposal to implement an international drug Pricing Index Model that would slash Medicare Part...

United Healthcare’s OptumRx Accused of Defrauding Benefit...

08/29/2018

Pharmacy Benefit Managers are being subjected to increasing scrutiny as purported drivers of pharmaceutical costs.  Justin Linder discusses the various fronts in the...

Charity for Gain: DOJ Eyes Patient Assistance Program...

07/31/2018

Pfizer's recent settlement with DOJ to resolve FCA kickback claims alleging coordination with a charitable patient assistance program is the most recent example of...

Hospitals Lose Challenge to Rate Cuts for Safety-Net...

07/18/2018

In a July 17th Order, the U.S. Court of Appeals for the District of Columbia dealt the latest blow to hospital groups’ challenge to the January 1, 2018 Medicare...

Are Private Equity Firms the New Health-Care Fraud...

06/04/2018

Private equity firms were placed on notice recently they may fall into an expanding False Claims Act liability net after the DOJ revealed it will proceed against one...

Justin C. Linder Quoted in March 6, 2018 Atlanta Journal-Constitution...

03/08/2018

In the March 6, 2018 edition of The Atlanta Journal-Constitution, Justin C. Linder discusses the potentially far-ranging implications on False Claims actions against...

Justin C. Linder Quoted in February 9, 2018 Bloomberg Pharmaceutical Law...

02/12/2018

Lobbying on behalf of biopharmaceutical manufacturers and 340B covered entities is spiking as the 340B discount drug program draws increased scrutiny from Congress and...

Start Working With Us

Trust